ICON Reports First Quarter 2020 Results
Reported revenue of $715.1 million representing a 6.0% YoY increase or 6.5% on a constant currency basis. Net business wins of $867 million; a book to bill of 1.21.
ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row
ICON recognised for specialised services offering across product development lifecycle, winning five awards overall.
ICON signs new Service Agreement with Pfizer
Agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.
ICON launches the Coronavirus Observatory
The Coronavirus Observatory applies powerful AI analysis and data visualisation to COVID-19 news and social media, providing updates on the latest vaccine trials.
ICON plc to Present at Barclays Global Healthcare Conference 2020
The presentation will be webcast live from 10.15am EDT, Tuesday, March 10, 2020.
ICON Acquires MedPass International
Acquisition expands ICON’s global Medical Device and Diagnostic Research Services
ICON Reports Fourth Quarter and Full Year 2019 Results
ICON reports Q4 & 2019 results. Full year reported revenue was $2,806 million. This represents a year on year increase of 8.1% or 9.6% on a constant currency basis
ICON Issues Financial Guidance for Full Year 2020
Full Year 2020 Revenue guidance in the range of $2,972 - $3,092 million, representing growth of 5.8 – 10.0%.
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020
ICON’s financial guidance for the year ended December 31, 2020 will be released by press release on Tuesday, January 14, 2020
ICON Wins Best Contract Research Organisation – Full-Service Providers at the 15th Annual Scrip Awards 2019
ICON awarded for capabilities and innovations in successful drug development and patient recruitment